A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. Cecchini M, Kortmansky JS, Cui C, Wei W, et al. Cancer 2020 Dec 22. doi: 10.1002/cncr.33379.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Cecchini M, Kortmansky JS, Cui C, Wei W, et al. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer 2020 Dec 22. doi: 10.1002/cncr.33379.
PMID: 33351187